The best corporate managers are always one step ahead. Salesforce is the second coming of Amazon.com...
Becton Dickinson Avoids Health-Care Flu
05/03/2007 12:00 am EST
Charles Carlson, editor of the DRIP Investor, says medical device maker Becton Dickinson is a solid growth company with strong businesses and a consistently rising dividend.
A lot of health-care stocks are under the weather. Generic competition, the lack of blockbuster drugs, problems in the product approval process, and litigation have all led to many health-care stocks being sickly performers. One exception to the group’s malaise has been Becton, Dickinson & Co. (NYSE: BDX).
The company, a provider of medical diagnostics and devices, is trading around its 52-week high near $80. Consistent earnings growth has been a major driver of these shares. The company’s steady performance, rising dividend stream and solid finances should fuel above-average market gains over the long term. The stock represents a worthwhile holding for the growth portion of a DRIP portfolio.
Becton, Dickinson manufactures and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products through its three segments: BD Medical (roughly 55% of annual sales), BD Diagnostics (30%), and BD Biosciences (15%).
Medical supplies include needles, syringes, intravenous catheters, surgical blades; critical-care monitoring devices, and ophthalmic surgical instruments. Diagnostic products include specimen-collection systems, blood-collection products, blood-culturing systems and rapid diagnostic assays. Products in the biosciences area include cell-imaging systems, monoclonal antibodies and kits, reagent systems for life sciences research, and diagnostic assays.
The company’s track record is impressive. Per-share profits have risen annually for well over a decade. Dividends, too, have consistently marched higher. In fact, Becton, Dickinson is a member of the small group of companies that has raised its dividend annually for at least the last 25 years.
Per share profits are expected to come in around $3.75 in fiscal 2007 ending September. That’s up from $3.28 per share in 2006. Becton Dickinson has beaten consensus earnings estimates in each of the last four quarters. The dividend was recently lifted 14% to a quarterly rate of $0.24½ per share. The stock yields 1.2%.
While not a cheap stock, Becton, Dickinson is not too pricey. These shares trade at 21x the fiscal 2007 consensus earnings estimate of $3.75 per share. That seems a fair multiple given the company’s impressive track record and growth potential. Please note that these shares have not split since 1998, so it would not be surprising to see a stock split from current levels.
Becton, Dickinson offers the attractive combination of dependable earnings growth and a steadily rising dividend stream. That one-two punch should lead to healthy returns for DRIP investors.
Becton, Dickinson’s direct-purchase plan permits initial purchases directly with an initial minimum of $250. The firm will waive the minimum if an investor agrees to automatic monthly investment via electronic debit of a bank account of at least $50. There is no enrollment fee. Purchase fees are just three cents per share.
Now about new highs being celebrated, amidst deterioration of a slew of internals: This suggests nei...
In part 1 of our commentary, we discussed the current Fundamental Gravity of our “Slowing Drag...
Some analysts are making the case that it’s time to look outside the U.S. at stocks in non-U.S...